Quantum BioPharma Ltd
Company Profile
Business description
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
Contact
1 Adelaide Street East
Suite 801
TorontoONM5C 2V9
CANT: +1 416 854-8884
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
Chart of the Week: BHP’s valuation hits historic levels
stocks
3 cheap wide moat growth stocks
stocks
ASX biotech expands diagnostics portfolio after FDA approval
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,883.50 | 9.00 | 0.10% |
| CAC 40 | 8,140.59 | 50.31 | 0.62% |
| DAX 40 | 25,537.75 | 135.47 | 0.53% |
| Dow JONES (US) | 51,461.90 | 631.21 | -1.21% |
| FTSE 100 | 10,688.47 | 30.34 | 0.28% |
| HKSE | 24,415.22 | 298.56 | -1.21% |
| NASDAQ | 25,978.43 | 3.14 | -0.01% |
| Nikkei 225 | 64,028.26 | 105.26 | 0.16% |
| NZX 50 Index | 13,684.65 | 61.93 | 0.45% |
| S&P 500 | 7,551.81 | 33.92 | -0.45% |
| S&P/ASX 200 | 8,705.90 | 9.40 | 0.11% |
| SSE Composite Index | 3,875.00 | 16.60 | -0.43% |